HLA基因型与抗甲状腺药物致粒细胞缺乏症的关联:系统综述与荟萃分析
该系统综述与荟萃分析检索了MEDLINE、Embase和CENTRAL数据库,纳入5项病例对照研究,共142例抗甲状腺药物致粒细胞缺乏症病例、1529例匹配的耐受对照和5945例健康对照。结果显示HLA-B*27:05、HLA-B*38:02和HLA-DRB1*08:03与抗甲状腺药物致粒细胞缺乏症相关,尤其在卡比马唑/甲巯咪唑所致者中关联更强。
要点
- HLA-B*38:02与抗甲状腺药物致粒细胞缺乏症关联最强(OR 19.85)。
- 排除丙硫氧嘧啶后,HLA-B*27:05和HLA-B*38:02的关联增强。
- HLA-B*27:05、HLA-B*38:02和HLA-DRB1*08:03与卡比马唑/甲巯咪唑致粒细胞缺乏症相关。
核心结论
- HLA-B*27:05、HLA-B*38:02和HLA-DRB1*08:03等位基因与抗甲状腺药物致粒细胞缺乏症相关,尤其在卡比马唑/甲巯咪唑所致者中。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和CENTRAL数据库(截至2018年6月16日),纳入5项病例对照研究,共142例抗甲状腺药物致粒细胞缺乏症病例、1529例匹配的耐受对照和5945例健康对照。
主要发现
- 抗甲状腺药物致粒细胞缺乏症与HLA-B*27:05(OR 10.97;95% CI 0.75-159.99)、HLA-B*38:02(OR 19.85;95% CI 7.94-49.57)和HLA-DRB1*08:03(OR 5.29;95% CI 3.44-8.14)相关。
- 排除丙硫氧嘧啶后,HLA-B*27:05和HLA-B*38:02的关联增强,OR分别为20.61(95% CI 5.21-81.58)和40.59(95% CI 13.24-124.47)。
- 与人群对照比较时,HLA-B*27:05、HLA-B*38:02和HLA-DRB1*08:03的关联仍显著,OR分别为7.37(95% CI 3.86-14.07)、36.43(95% CI 12.80-103.70)和5.42(95% CI 2.36-12.47)。
临床怎么用
- 对于携带HLA-B*27:05、HLA-B*38:02或HLA-DRB1*08:03等位基因的患者,使用卡比马唑/甲巯咪唑时应警惕粒细胞缺乏症风险。
- 临床可考虑在启动抗甲状腺药物治疗前检测上述HLA等位基因,以辅助风险评估。
局限性
- 纳入研究数量较少(5项),样本量有限。
- HLA-B*27:05与抗甲状腺药物致粒细胞缺乏症的关联在总体分析中置信区间宽且无统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Antithyroid drug (ATD)-induced agranulocytosis is a life-threatening adverse drug reaction. Previous studies suggested that HLA genotypes may play an important role in ATD-induced agranulocytosis. To examine the associations between HLA genotypes and ATD-induced agranulocytosis, we conducted a systematic review and meta-analysis of pharmacogenomics studies. METHODS: We searched the MEDLINE, Embase and CENTRAL databases on 16 June 2018 for case-control studies on the associations between HLA genotypes with ATD-induced agranulocytosis. The Newcastle-Ottawa scale was used to evaluate the risk of bias of included studies. We conducted random-effects model meta-analysis to obtain pooled odds ratios (ORs) with 95% confidence intervals (CIs) to determine the associations between HLA genotypes and ATD-induced agranulocytosis. RESULTS: We included 5 studies with 142 ATD-induced agranulocytosis cases, 1529 matched ATD-tolerant controls and 5945 healthy controls. The risk of bias of included studies was generally low. ATD-induced agranulocytosis was associated with HLA-B*27:05 (OR 10.97; 95% CI 0.75-159.99), HLA-B*38:02 (OR 19.85; 95% CI 7.94-49.57) and HLA-DRB1*08:03 (OR 5.29; 95% CI 3.44-8.14). After excluding propylthiouracil, the associations of ATD-induced agranulocytosis with HLA-B*27:05 and HLA-B*38:02 were strengthened (OR being 20.61 (95% CI 5.21-81.58) and 40.59 (95% CI 13.24-124.47), respectively). The associations of ATD-induced agranulocytosis with HLA-B*27:05, HLA-B*38:02 and HLA-DRB1*08:03 remained significant when compared to population controls (OR being 7.37 (95% CI 3.86-14.07), 36.43 (95% CI 12.80-103.70) and 5.42 (95% CI 2.36-12.47), respectively). HLA-B*27:05, HLA-B*38:02, and HLA-DRB1*08:03 alleles were associated with ATD-induced agranulocytosis, especially in carbimazole/methimazole-induced agranulocytosis. CONCLUSIONS: HLA-B*27:05, HLA-B*38:02 and HLA-DRB1*08:03 alleles were associated with ATD-induced agranulocytosis, especially in carbimazole/methimazole-induced agranulocytosis.
引用
- Chen WT, Chi CC. Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: A systematic review and meta-analysis of pharmacogenomics studies. Br J Clin Pharmacol. 2019. PMID: 31108563. doi:10.1111/bcp.13989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。